CLINICAL REGISTRY ON PATIENT POPULATION WITH MULTIFOCAL ATHEROSCLEROSIS IN THE RUSSIAN FEDERATION AND EURASIAN COUNTRIES – KAMMA

Highlights

Developing international registry that would unify different patient populations not represented in other registries and studies, and include patients with both manifested and subclinical atherosclerosis, is crucial for cardiovascular field. The collected data can be used in national guidelines, teaching and learning guides, and in clinical practice.

Abstract

Multifocal atherosclerosis (MFA) is one of the key issues in modern medicine. Several vascular beds are involved in the pathological process in every fifth patient with detected atherosclerosis. Moreover, patients with MFA have high risk of ischemic events, lower quality of life, shorter life expectancy and disability. “The Eurasian Association of Internal medicine” proposed to create a registry on real clinical practice in order to collect data on the frequency, detection methods, clinical course, risk factors and outcomes of patients with MFA in specialized centers in Russia and Commonwealth of Independent States (Republic of Kazakhstan, Republic of Uzbekistan, Republic of Belarus).

1. Bokeria L.A., Golukhova E.Z. Klinicheskaya kardiologia: diagnostika i lechenie. In 3 vol. Moscow: A.N. Bakulev National Medical Research Center of Cardiovascular Surgery Publ.; 2011. 662 p. (In Russian)

2. Meyrier A. Athérosclérose et reins [Atherosclerosis and the kidney]. Nephrol Ther. 2005;1(3):183-202. French. doi: 10.1016/j.nephro.2005.06.006.

3. Beita A.K.V., Whayne T.F. The Superior Mesenteric Artery: From Syndrome in the Young to Vascular Atherosclerosis in the Old. Cardiovasc Hematol Agents Med Chem. 2019;17(2):74-81. doi: 10.2174/1871525717666190920100518.

4. Ohman E.M., Bhatt D.L., Steg P.G., Goto S., Hirsch A.T., Liau C.S., Mas J.L., Richard A.J., Röther J., Wilson P.W.; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(4):786. doi: 10.1016/j.ahj.2005.11.004.

5. Prudnikov A.R., Shchupakova A.N. Multifocal atherosclerosis is one of the major risk factors that accelerates the development of acute cardiovascular events. Medical academic journal. 2018;18(2):29-42. doi: 10.17816/MAJ18229-42. (In Russian)

6. Steffel J., Eikelboom J.W., Anand S.S., Shestakovska O., Yusuf S., Fox K.A.A. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020;142(1):40-48. doi: 10.1161/CIRCULATIONAHA.120.046048.

7. Fox K.A.A., Anand S.S., Aboyans V., Cowie M.R., Debus E.S., Zeymer U., Monje D., Vogtländer K., Lawatscheck R., Gay A. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. Am Heart J. 2020;222:166-173. doi: 10.1016/j.ahj.2020.01.015.

8. Fox K.A.A., Aboyans V., Debus E.S., Zeymer U., Cowie M.R., Patel M., Welsh R.C., Bosch J., Gay A., Vogtländer K., Anand S.S. Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. Eur Heart J Cardiovasc Pharmacother. 2022:pvac028. doi: 10.1093/ehjcvp/pvac028.

9. Fowkes F.G., Low L.P., Tuta S., Kozak J.; AGATHA Investigators. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861-7. doi: 10.1093/eurheartj/ehl114.

10. Bhatt D.L., Peterson E.D., Harrington R.A., Ou F.S., Cannon C.F., Gibson C.M., Kleiman N.S., Brindis R.G., Peacock W.F., Brener S.J., Menon V., Smith S.C., Pollack C.V. Jr, Gibler W.B., Ohman E.M., Roe M.T.; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10):1195-202. doi: 10.1093/eurheartj/ehp099.

11. Sumin A.N., Korok E.V., R.A. Gaifulin, A.V. Bezdenezhnykh, Ivanov S.V., Barbarash O.L.. Gender-specific features of the prevalence and clinical manifestations of multifocal atherosclerosis. Clinical Medicine. 2014;1:34–40. (In Russian).

12. Sumin A.N., Gayfulin R.A., Bezdenezhnykh A.V., Moskin M.G., Korok E.V., Kaprovich A.V., Ivanov S.V., Barbarash O.L., Barbarash L.S. Rasprostranennost' mul'tifokal'nogo ateroskleroza v razlichnykh vozrastnykh gruppakh. Cardiology. 2012;52(6):28–34. (In Russian).

13. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Il’in V.A., Konradi A.O., Libis R.A., Minakov E.V., Nedogoda S.V., Oschepkova E.V., Romanchuk S.V., Rotar O.P., Trubacheva I.A., Deev A.D., Shalnova S.A., Chazova I.E., Shlyakhto E.V., Boytsov S.A., Balanova Yu.A., Gomyranova N.V., Evstifeeva S.E., Kapustina A.V., Litinskaya O.A., Mamedov M.N., Metelskaya V.A., Oganov R.G., Suvorova E.I., Khudyakov M.B., Baranova E.I., Kasimov R.A., Shabunova A.A., Ledyaeva A.A., Chumachek E.V., Azarin O.G., Babenko N.I., Bondartsov L.V., Furmenko G.I., Khvostikova A.E., Belova O.A., Nazarova O.A., Shutemova E.A., Barbarash O.L., Danilchenko Y.V., Indukaeva E.V., Maksimov S.A., Mulerova T.A., Skripchenko A.E., Cherkass N.V., Basyrova I.R., Isaeva E.N., Kondratenko V.Yu., Lopina E.A., Safonova D.V., Gudkova S.A., Cherepanova N.A., Kaveshnikov V.S., Karpov R.S., Serebryakova V.N., Medvedeva I.V., Storozhok M.A., Shava V.P., Shalaev S.V., Gutnova S.K., Tolparov G.V. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. doi 10.15829/1728-8800-2014-6-4-11 (In Russian)